Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew


IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 8, Issue 5

Issues

Volume 10 (2015)

The effect of orlistat on body weight in obese Czech adults

Vladimír Pavlík
  • Department of Military Hygiene, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jana Fajfrová
  • Department of Military Hygiene, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Eva Drahokoupilová
Published Online: 2013-09-18 | DOI: https://doi.org/10.2478/s11536-013-0194-1
  • [1] Reaven P., Metabolic syndrome, J. Insur. Med., 2004, 36, 132–142 Google Scholar

  • [2] Ginter E, Simko V., Adult obesity at the beginning od the 21st century: epidemiology, pathophysiology and health risk, Bratisl. Lek. Listy, 2008, 109, 224–230 Google Scholar

  • [3] Waden T.A, Berkowitz R.I, Womble L.G., Randomized trial of lifestyle modification and pharmacotherapy for obesity, N. Engl. J. Med., 2005, 353, 2111–2116 http://dx.doi.org/10.1056/NEJMoa050156CrossrefGoogle Scholar

  • [4] Svendsen M, Tonstad S., Orlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders, Nutr. J., 2011, 8, 10–21 Web of ScienceGoogle Scholar

  • [5] Torp-Pedersen C, Caterson I, Coutinho W., Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial, Eur. Heart. J., 2007, 28(23), 2915–2923 http://dx.doi.org/10.1093/eurheartj/ehm217Web of ScienceCrossrefGoogle Scholar

  • [6] James W.P, Caterson I.D, Coutinho W., Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects, N. Engl. J. Med., 2010, 363(10), 905–917 http://dx.doi.org/10.1056/NEJMoa1003114Web of ScienceCrossrefGoogle Scholar

  • [7] Hainer V., Comparative efficiency and safety of pharmacological approaches to the management of obesity. Diabetes Care, 2011, 34, 349–354 http://dx.doi.org/10.2337/dc11-s255CrossrefWeb of ScienceGoogle Scholar

  • [8] Bray G.A., Medical therapy for obesity, Mt. Sinai J. Med., 2010, 77(5), 407–417 http://dx.doi.org/10.1002/msj.20207CrossrefGoogle Scholar

  • [9] Li Z, Maglione M, Tu W., Pharmacologic treatment of obesity, Ann. Intern. Med., 2005, 142, 532–538 http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00012CrossrefGoogle Scholar

  • [10] Hainer V., Orlistat a perspektivy farmakoterapie obezity, JAMA, 1999, 7, 371–373 Google Scholar

  • [11] Li M.F, Cheung B.M., Rise and fall of anti-obesity drugs, World J. Diabetes, 2011, 15(2), 19–23 http://dx.doi.org/10.4239/wjd.v2.i2.19CrossrefGoogle Scholar

  • [12] Jain S.S, Ramajane S.J, Akat P.B., Evaluation of efficacy and safety of orlistat in obese patients, Indian J. Endocrinol. Metab., 2011, 15(2), 99–104 http://dx.doi.org/10.4103/2230-8210.81938CrossrefGoogle Scholar

  • [13] Derosa G, Maffioli P, Salvadeo S.A., Comparison of orlistat treatment and placebo in obese type 2 diabetic patients, Expert Opin. Pharmacother., 2010, 11(12), 1971–1982 http://dx.doi.org/10.1517/14656566.2010.493557CrossrefWeb of ScienceGoogle Scholar

  • [14] Minarčíková I., Farmakoekonomické aspekty ve farmakoterapii obezity, Česká a Slov. Farm., 2003, 52, 258–261 Google Scholar

  • [15] Hainer V., Comment to the article: Assessment of morbid obesity treatment cost efficiency in the Czech Republic, Diab. Metab. Endokr., 2012, 15(3), 199–200 Google Scholar

  • [16] Russell-Jones D., Gough S. Recent advances in incretin-based therapies, Clin. Endocrinol. 2012, 77(4), 489–499 http://dx.doi.org/10.1111/j.1365-2265.2012.04483.xWeb of ScienceCrossrefGoogle Scholar

  • [17] Hayes M.R., De Jonghe B.C., Kanoski S.E., Role of the glucagon-like-peptide-1 receptor in the control of energy balance, Physiology and Behavior, 2010, 100(5), 503–510 http://dx.doi.org/10.1016/j.physbeh.2010.02.029CrossrefGoogle Scholar

  • [18] Allison D.B., Gadde K.M., Garvey W.T., Controlledrelease phentermine/topiramate in severely obese adults: a randomized controlled trial, Obesity, 2012, 20(2), 330–42 http://dx.doi.org/10.1038/oby.2011.330Web of ScienceCrossrefGoogle Scholar

  • [19] Gadde K.M., Day W.W., Low-dose, controlledrelease phentermin/topiramate for reduction of weight, Obesity reviews from 11th International Congress on Obesity, 11–15 July 2010 Stockholm, 2010, 11(1), 42–43 Google Scholar

  • [20] Ornellas T., Chavez B., A New Approach to Weight Loss in Obese Adults, Pharmacy and Therapeutics, 2011, 36(5), 255–256, 261–262 Google Scholar

About the article

Published Online: 2013-09-18

Published in Print: 2013-10-01


Citation Information: Open Medicine, Volume 8, Issue 5, Pages 553–557, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-013-0194-1.

Export Citation

© 2013 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in